Roivant Sciences Ltd. (ROIV) shareholders
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dan Oren | 102,849,443 | – | 13G (passive) amendment | Dec 31, 2023 |
| FMR LLC Joint filing with Abigail P. Johnson (11.80%) | 85,575,552 | 11.80% | 13G (passive) amendment | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (10.30%) | 73,641,253 | 10.30% | 13G (passive) amendment | Feb 27, 2026 |
| BlackRock, Inc. | 59,285,183 | 8.20% | 13G (passive) amendment | Sep 30, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley Investment Management Inc. (5.50%) | 40,693,386 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
| SVF Holdings (UK) LLP Joint filing with SB Investment Advisers (UK) Limited (5.80%), SoftBank Vision Fund L.P. (5.80%) and 1 more | 40,315,127 | 5.80% | 13G (passive) amendment | Sep 30, 2025 |
| Viking Global Investors LP Joint filing with Halvorsen Ole Andreas (5.02%), Ott David C. (5.02%) and 1 more | 34,237,779 | 5.02% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ROIV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 81,020,390 | 11.22% | $2.87B | +3,039,137 | 0.12% |
| BlackRock, Inc. | 48,236,091 | 6.68% | $1.71B | +3,981,831 | 0.03% |
| Morgan Stanley | 42,592,905 | 5.90% | $1.51B | −9,235,420 | 0.08% |
| QVT Financial LP | 23,723,074 | 3.28% | $839.56M | −1,438,163 | 50.52% |
| Vanguard Capital Management LLC | 22,123,198 | 3.06% | $782.94M | +1,442,626 | 0.02% |
| Vanguard Portfolio Management LLC | 21,641,339 | 3.00% | $765.89M | +1,802,641 | 0.03% |
| Goldman Sachs Group Inc | 18,556,458 | 2.57% | $656.71M | +7,444,867 | 0.06% |
| State Street Corp | 17,795,975 | 2.46% | $629.80M | +1,609,362 | 0.02% |
| UBS Group AG | 17,466,641 | 2.42% | $618.14M | −5,152,831 | 0.08% |
| Assenagon Asset Management S.A. | 16,725,904 | 2.32% | $591.93M | +9,649,416 | 0.37% |
| Farallon Capital Management LLC | 14,309,000 | 1.98% | $506.40M | +4,634,000 | 2.34% |
| Geode Capital Management, LLC | 11,674,380 | 1.62% | $425.54M | +1,491,903 | 0.02% |
| Adage Capital Partners Gp, L.L.C. | 10,349,328 | 1.43% | $366.26M | −2,444,769 | 0.51% |
| Two Seas Capital LP | 8,475,356 | 1.17% | $299.94M | −852,935 | 5.94% |
| Perceptive Advisors LLC | 8,085,461 | 1.12% | $286.14M | −200,000 | 4.30% |
| Patient Square Capital LP | 8,020,928 | 1.11% | $283.86M | −145,119 | 43.97% |
| Invesco Ltd. | 7,531,192 | 1.04% | $266.53M | +1,092,047 | 0.02% |
| Darwin Global Management, Ltd. | 6,747,300 | 0.93% | $234.33M | −50,000 | 6.23% |
| Aqr Capital Management LLC | 6,633,560 | 0.92% | $234.03M | +686,702 | 0.08% |
| Viking Global Investors LP | 6,271,467 | 0.87% | $221.95M | −380,981 | 0.63% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 498 | 564M | 78.1% | 100 / 202 | 141 / 40 | 83M | 45M |
| Q1 2026 | 444 | 531M | 73.5% | 97 / 174 | 121 / 47 | 125M | 62M |
| Q4 2025 | 400 | 509M | 70.5% | 110 / 150 | 94 / 40 | 106M | 98M |
| Q3 2025 | 338 | 503M | 69.6% | 59 / 124 | 96 / 56 | 50M | 63M |
| Q2 2025 | 338 | 516M | 71.5% | 61 / 115 | 110 / 35 | 53M | 95M |
| Q1 2025 | 313 | 558M | 77.2% | 57 / 91 | 107 / 59 | 27M | 29M |
| Q4 2024 | 319 | 563M | 77.9% | 69 / 93 | 104 / 41 | 31M | 40M |
| Q3 2024 | 294 | 572M | 79.2% | 54 / 122 | 69 / 52 | 109M | 47M |
| Q2 2024 | 294 | 547M | 75.7% | 64 / 102 | 83 / 26 | 55M | 111M |
| Q1 2024 | 259 | 604M | 83.6% | 69 / 92 | 63 / 34 | 139M | 99M |
| Q4 2023 | 225 | 564M | 78.1% | 61 / 86 | 52 / 41 | 84M | 65M |
| Q3 2023 | 206 | 546M | 75.6% | 53 / 88 | 47 / 27 | 88M | 40M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
151 funds held ROIV in Q2 2026, 88% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ROIV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 15,987,737 | 2.21% | $565.81M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 11,546,280 | 1.60% | $408.62M | 0.22% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 6,658,616 | 0.92% | $235.65M | 0.50% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF | 5,219,192 | 0.72% | $176.98M | 2.47% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 5,168,626 | 0.72% | $182.92M | 0.19% | Jun 30, 2026 |
| Vanguard Explorer Fund | 2,969,485 | 0.41% | $100.70M | 0.46% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 1,165,423 | 0.16% | $39.52M | 0.08% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 1,128,232 | 0.16% | $33.84M | 0.18% | May 31, 2026 |
| iShares Russell 1000 Value ETF | 1,093,652 | 0.15% | $38.70M | 0.05% | Jun 30, 2026 |
| Vanguard S&p Mid-Cap 400 Index Fund | 719,473 | 0.10% | $21.58M | 0.39% | May 31, 2026 |
| Invesco BuyBack AchieversTM ETF | 582,864 | 0.08% | $19.76M | 0.87% | Jul 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 519,187 | 0.07% | $18.37M | 0.01% | Jun 30, 2026 |
| Bridge Builder Large Cap Growth Fund | 505,669 | 0.07% | $17.90M | 0.06% | Jun 30, 2026 |
| Vanguard Total World Stock Index Fund | 416,293 | 0.06% | $14.12M | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 380,966 | 0.05% | $12.92M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mayukh Sukhatme | President & CIO, Director | 20,054,401 | 2.78% | Nov 12, 2026 |
| Matthew Gline | CEO, Director | 16,391,229 | 2.27% | Nov 12, 2026 |
| Richard Pulik | CFO | 222,046 | 0.03% | Nov 12, 2026 |
| Eric Venker | President & Immunovant CEO | 811,211 | 0.11% | Nov 12, 2026 |
| Frank Torti | President and Vant Chair | 12,306,950 | 1.70% | Nov 12, 2026 |
| Jennifer Humes | Chief Accounting Officer | 106,419 | 0.01% | Sep 22, 2026 |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | 0.02% | Feb 24, 2025 |
| James C. Momtazee | Director | 112,265 | 0.02% | Oct 27, 2026 |
| Epperly Melissa B, | Director | 15,351 | 0.00% | Oct 27, 2026 |
| Ilan Oren | Director | 124,490 | 0.02% | Oct 27, 2026 |
| Daniel Allen Gold | Director | 22,654,981 | 3.14% | Sep 18, 2026 |
| Keith S. Manchester | Director | 15,442,623 | 2.14% | Sep 18, 2026 |
| Meghan Fitzgerald | Director | 41,162 | 0.01% | Sep 18, 2026 |
| Financial LP QVT | – | 13,689,166 | 1.90% | Jun 30, 2026 |
| Vivek Ramaswamy | 10% owner | 47,490,320 | 6.57% | Dec 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frank Torti President and Vant Chair | Nov 12, 2026 | Tax withholding | −12,800 | $41.85 | $535.68K | 12,306,950 |
| Frank Torti President and Vant Chair | Nov 12, 2026 | Other | −62,493 | $41.13 | $2.57M | 12,319,750 |
| Frank Torti President and Vant Chair | Nov 12, 2026 | Other | −329,550 | $40.36 | $13.30M | 12,382,243 |
| Matthew Gline CEO, Director | Nov 12, 2026 | Tax withholding | −1,600 | $41.85 | $66.96K | 16,391,229 |
| Matthew Gline CEO, Director | Nov 12, 2026 | Other | −7,809 | $41.13 | $321.18K | 16,392,829 |
| Matthew Gline CEO, Director | Nov 12, 2026 | Other | −41,179 | $40.36 | $1.66M | 16,400,638 |
| Mayukh Sukhatme President & CIO, Director | Nov 12, 2026 | Tax withholding | −1,737 | $41.85 | $72.69K | 18,396,703 |
| Mayukh Sukhatme President & CIO, Director | Nov 12, 2026 | Other | −8,482 | $41.13 | $348.86K | 18,398,440 |
| Mayukh Sukhatme President & CIO, Director | Nov 12, 2026 | Other | −44,723 | $40.36 | $1.81M | 18,406,922 |
| Frank Torti President and Vant Chair | Nov 11, 2026 | Other | −151,293 | $42.01 | $6.36M | 12,711,793 |
| Frank Torti President and Vant Chair | Nov 11, 2026 | Other | −240,755 | $41.63 | $10.02M | 12,863,086 |
| Matthew Gline CEO, Director | Nov 11, 2026 | Other | −18,905 | $42.01 | $794.20K | 16,441,817 |
| Matthew Gline CEO, Director | Nov 11, 2026 | Other | −30,083 | $41.63 | $1.25M | 16,460,722 |
| Mayukh Sukhatme President & CIO, Director | Nov 11, 2026 | Other | −20,533 | $42.01 | $862.59K | 18,451,645 |
| Mayukh Sukhatme President & CIO, Director | Nov 11, 2026 | Other | −32,672 | $41.63 | $1.36M | 18,472,178 |
| Richard Pulik CFO | Nov 11, 2026 | Sale | −47,635 | $41.89 | $2.00M | 222,046 |
| Richard Pulik CFO | Nov 11, 2026 | Sale | −82,170 | $42.03 | $3.45M | 269,681 |
| Richard Pulik CFO | Nov 11, 2026 | Sale | −45,195 | $41.47 | $1.87M | 351,851 |
| Richard Pulik CFO | Nov 11, 2026 | Option exercise | +127,365 | $3.85 | $490.36K | 397,046 |
| Eric Venker President & Immunovant CEO | Nov 10, 2026 | Sale(10b5-1 plan) | −29,749 | $41.00 | $1.22M | 811,211 |
| Eric Venker President & Immunovant CEO | Nov 10, 2026 | Sale(10b5-1 plan) | −158,194 | $40.44 | $6.40M | 840,960 |
| Frank Torti President and Vant Chair | Nov 10, 2026 | Other | −218,369 | $41.13 | $8.98M | 13,103,841 |
| Frank Torti President and Vant Chair | Nov 10, 2026 | Other | −173,683 | $40.43 | $7.02M | 13,322,210 |
| Matthew Gline CEO, Director | Nov 10, 2026 | Other | −32,490 | $41.13 | $1.34M | 16,490,805 |
| Matthew Gline CEO, Director | Nov 10, 2026 | Other | −25,841 | $40.43 | $1.04M | 16,523,295 |
| Mayukh Sukhatme President & CIO, Director | Nov 10, 2026 | Other | −32,882 | $41.13 | $1.35M | 18,504,850 |
| Mayukh Sukhatme President & CIO, Director | Nov 10, 2026 | Other | −26,152 | $40.43 | $1.06M | 18,537,732 |
| Richard Pulik CFO | Nov 10, 2026 | Sale | −125,000 | $41.20 | $5.15M | 269,681 |
| Richard Pulik CFO | Nov 10, 2026 | Option exercise | +125,000 | $3.85 | $481.25K | 394,681 |
| Eric Venker President & Immunovant CEO | Nov 3, 2026 | Sale(10b5-1 plan) | −200,000 | $36.31 | $7.26M | 999,154 |
| Eric Venker President & Immunovant CEO | Oct 28, 2026 | Sale(10b5-1 plan) | −200,000 | $36.59 | $7.32M | 1,199,154 |
| Epperly Melissa B, Director | Oct 23, 2026 | Tax withholding | −116 | $36.49 | $4.23K | 15,351 |
| Epperly Melissa B, Director | Oct 23, 2026 | Award | +513 | – | – | 15,467 |
| Ilan Oren Director | Oct 23, 2026 | Award | +810 | – | – | 124,490 |
| James C. Momtazee Director | Oct 23, 2026 | Tax withholding | −77 | $36.49 | $2.81K | 112,265 |
| James C. Momtazee Director | Oct 23, 2026 | Award | +383 | – | – | 112,342 |
| Eric Venker President & Immunovant CEO | Oct 20, 2026 | Sale(10b5-1 plan) | −14,144 | $35.42 | $500.98K | 1,399,154 |
| Eric Venker President & Immunovant CEO | Oct 20, 2026 | Sale(10b5-1 plan) | −185,856 | $35.09 | $6.52M | 1,413,298 |
| Mayukh Sukhatme President & CIO, Director | Oct 16, 2026 | Tax withholding | −19,976 | $33.53 | $669.80K | 18,563,884 |
| Matthew Gline CEO, Director | Oct 16, 2026 | Tax withholding | −34,638 | $33.53 | $1.16M | 16,549,136 |
| Epperly Melissa B, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −900 | $36.57 | $32.91K | 14,954 |
| Epperly Melissa B, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −16,850 | $36.08 | $607.95K | 15,854 |
| Epperly Melissa B, Director | Oct 1, 2026 | Option exercise | +17,750 | $4.46 | $79.17K | 32,704 |
| Mayukh Sukhatme President & CIO, Director | Sep 30, 2026 | Tax withholding | −46,879 | $36.57 | $1.71M | 18,583,860 |
| Eric Venker President & Immunovant CEO | Sep 30, 2026 | Sale(10b5-1 plan) | −200,000 | $36.62 | $7.32M | 1,599,154 |
| Eric Venker President & Immunovant CEO | Sep 30, 2026 | Option exercise | +200,000 | $3.85 | $770.00K | 1,799,154 |
| Matthew Gline CEO, Director | Sep 30, 2026 | Tax withholding | −76,171 | $36.57 | $2.79M | 16,583,774 |
| Frank Torti President and Vant Chair | Sep 30, 2026 | Tax withholding | +40,309 | $36.57 | $1.47M | 13,495,893 |
| Jennifer Humes Chief Accounting Officer | Sep 20, 2026 | Tax withholding | −3,880 | $39.77 | $154.31K | 106,419 |
| Richard Pulik CFO | Sep 20, 2026 | Tax withholding | −2,129 | $39.77 | $84.67K | 269,681 |
| Meghan Fitzgerald Director | Sep 16, 2026 | Award | +5,054 | – | – | 41,162 |
| Keith S. Manchester Director | Sep 16, 2026 | Award | +5,054 | – | – | 1,753,457 |
| James C. Momtazee Director | Sep 16, 2026 | Award | +5,054 | – | – | 111,959 |
| Daniel Allen Gold Director | Sep 16, 2026 | Award | +5,054 | – | – | 8,965,815 |
| Ilan Oren Director | Sep 16, 2026 | Award | +5,054 | – | – | 123,680 |
| Epperly Melissa B, Director | Sep 16, 2026 | Award | +5,054 | – | – | 14,954 |
| Epperly Melissa B, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −600 | $40.38 | $24.23K | 9,900 |
| Epperly Melissa B, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,338 | $39.65 | $172.00K | 10,500 |
| Meghan Fitzgerald Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,712 | $39.68 | $186.97K | 36,508 |
| Meghan Fitzgerald Director | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $40.45 | $16.18K | 36,108 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Roivant Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 102,373 shares on Sep 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mayukh Sukhatme Officer, Director | Nov 10, 2026 | 173,725 | $7.12M | Nov 10, 2026 | Performance Stock Units |
| Matthew Gline Officer, Director | Nov 10, 2026 | 164,136 | $6.73M | Nov 10, 2026 | Performance Stock Units |
| Frank Torti Officer | Nov 10, 2026 | 1,234,964 | $50.73M | Nov 10, 2026 | Performance Stock Units |
| Richard Pulik Officer, Director | Nov 10, 2026 | 125,000 | $5.15M | Nov 10, 2026 | Exercise of Options Under a Registered Plan |
| Frank Torti Officer | Nov 10, 2026 | 1,234,964 | $50.73M | Nov 10, 2026 | Performance Stock Units |
| Matthew Gline Officer, Director | Nov 10, 2026 | 164,136 | $6.73M | Nov 10, 2026 | Performance Stock Units |
| Mayukh Sukhatme Officer, Director | Nov 10, 2026 | 173,725 | $7.12M | Nov 10, 2026 | Performance Stock Units |
| Eric Venker Officer | Nov 10, 2026 | 187,943 | $7.62M | Nov 10, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Eric Venker Officer | Nov 3, 2026 | 200,000 | $7.26M | Nov 3, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Eric Venker Officer | Oct 28, 2026 | 200,000 | $7.32M | Oct 28, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Eric Venker Officer | Oct 20, 2026 | 200,000 | $7.02M | Oct 20, 2026 | RSU Grant 019326 - Grant Date 04/20/2022 |
| Eric Venker Officer | Sep 30, 2026 | 200,000 | $7.32M | Sep 30, 2026 | Options Exercise - Grant Date 04/20/2022 |
| Epperly Melissa B, Director | Sep 15, 2026 | 22,688 | $930.66K | Sep 15, 2026 | Exercise of Stock Options |
| Meghan Fitzgerald Officer | Sep 15, 2026 | 5,112 | $209.69K | Sep 15, 2026 | Restricted Stock Units |
| Meghan Fitzgerald Director | Sep 8, 2026 | 20,000 | $698.60K | Sep 8, 2026 | Exercise of Stock Options |
See a number that looks wrong?